Evidence map›Paper›PMID 39821191›Full record

ArticleDrugs - real world outcomes2025

Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.

Bruno Fautrel, Yoram Bouhnik, Carine Salliot, Franck Carbonnel, Mathurin Fumery, Christophe Bernardeau, Yves Maugars, Mathurin Flamant, Fabienne Coury, Ben Braithwaite and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Drugs - real world outcomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Bruno FautrelSorbonne University, AP-HP, Hôpital de La Pitié-Salpêtrière, INSERM UMRS 1136, Paris, France.ORCID http://orcid.org/0000-0001-8845-4274
Yoram BouhnikParis IBD Center, Groupe hospitalier privé Ambroise Paré-Hartmann, Neuilly sur Seine, France.ORCID http://orcid.org/0000-0002-5787-4943
Carine SalliotRheumatology Department, Centre Hospitalier Universitaire d'Orléans, Orléans, France.ORCID http://orcid.org/0000-0003-1066-4161
Franck CarbonnelHôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France.ORCID http://orcid.org/0000-0002-4779-5168
Mathurin FumeryDépartement de Gastroentérologie, CHU Amiens, Amiens, France.
Christophe BernardeauClinique François Chénieux, Limoges, France.ORCID http://orcid.org/0000-0002-2337-2902
Yves MaugarsINSERM, UMR 1229, RMeS, Regenerative Medicine and Skeleton, Université de Nantes, ONIRIS, Nantes, France.ORCID http://orcid.org/0000-0002-5131-8524
Mathurin FlamantDépartement de Gastroentérologie, Clinique Jules Verne, Nantes, France.ORCID http://orcid.org/0000-0002-8076-7046
Fabienne CouryRheumatology Department, Lyon Sud Hospital, Hospices Civils de Lyon, University of Lyon, Lyon, France.ORCID http://orcid.org/0000-0002-9175-8620
Ben BraithwaiteSanoïa e-Health Services, 188 av 2nd Division Blindée, 13420, Gémenos, France. bbraithwaite@sanoia.com.ORCID http://orcid.org/0000-0002-7378-1034
Salima HatebBiogen France SAS, Gastroenterology and Rhumatologie, Biosimilars, Courbevoie, France.
Janet AddisonBiogen IDEC, Clinical Research, Biosimilars, Maidenhead, UK.
PERFUSE investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39821191
PMCPMC11829871

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.